First Hawaiian Bank Acquires 19,629 Shares of DexCom, Inc. (NASDAQ:DXCM)

First Hawaiian Bank raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 556.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,159 shares of the medical device company’s stock after acquiring an additional 19,629 shares during the quarter. First Hawaiian Bank’s holdings in DexCom were worth $1,801,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DXCM. B. Riley Wealth Advisors Inc. grew its position in DexCom by 4.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after acquiring an additional 162 shares during the last quarter. Sachetta LLC increased its stake in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares in the last quarter. Crossmark Global Holdings Inc. raised its holdings in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after buying an additional 182 shares during the last quarter. Perennial Investment Advisors LLC lifted its position in DexCom by 7.4% during the 2nd quarter. Perennial Investment Advisors LLC now owns 3,156 shares of the medical device company’s stock worth $358,000 after buying an additional 217 shares in the last quarter. Finally, Riverview Trust Co grew its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Up 0.9 %

DXCM opened at $80.09 on Thursday. The firm’s fifty day moving average is $76.59 and its two-hundred day moving average is $79.52. The firm has a market cap of $31.28 billion, a PE ratio of 47.96, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Analysts Set New Price Targets

DXCM has been the topic of a number of research reports. Oppenheimer reduced their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Wells Fargo & Company raised their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Citigroup lifted their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $98.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.